United States: Breaking: Judgment In Regeneron v. Mylan (Aflibercept) BPCIA Case Finding Some Claims Of Asserted Patents Valid And Infringed - Goodwin Procter LLP

Mondaq

08 Jan 2024 0 shares 3 views

United States: Breaking: Judgment In Regeneron v. Mylan (Aflibercept) BPCIA Case Finding Some Claims Of Asserted Patents Valid And Infringed - Goodwin Procter LLP

Mondaq

Published 08 Jan 2024

As previously reported by Big Molecule Watch, trial in Regeneron's BPCIA case against Biocon regarding Biocon's proposed aflibercept biosimilar concluded on June 15, 2023 in the Northern District of West Virginia.

Full Article

United States: PTAB Issues Final Written Decisions Finding Claims Of Aflibercept-Related Patents Invalid - Goodwin Procter LLP

On January 9, 2024, the PTAB issued final written decisions in IPR2022-01225 and IPR2022-01226, filed by Mylan on two Regeneron..

Mondaq 26 Jan 2024

United States: Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation - Goodwin Procter LLP

As we have previously reported, in November 2023 Regeneron Pharmaceuticals, Inc. ("Regeneron") filed complaints against Celltrion,..

Mondaq 11 Jan 2024

United States: Breaking: Judgment In Regeneron v. Mylan (Aflibercept) BPCIA Case Finding Some Claims Of Asserted Patents Valid And Infringed - Goodwin Procter LLP

United States: Breaking: Judgment In Regeneron v. Mylan (Aflibercept) BPCIA Case Finding Some Claims Of Asserted Patents Valid And Infringed - Goodwin Procter LLP

You might like

Related news coverage

United States: PTAB Issues Final Written Decisions Finding Claims Of Aflibercept-Related Patents Invalid - Goodwin Procter LLP

United States: Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation - Goodwin Procter LLP

Advertisement